Lumacaftor is in clinical development for the treatment of cystic fibrosis.
Reviewed: January 9, 2015
Lumacaftor is currently in clinical development and under review for approval as a prescription drug for the treatment of cystic fibrosis. It is manufactured by Vertex Pharmaceuticals, but it is not yet approved by any regulatory agency worldwide.
Lumacaftor targets the underlying genetic mutation that causes cystic fibrosis. It is used in combination with the drug ivacaftor.
Common side effects of lumacaftor include pulmonary infections and disease exacerbations, cough, headache, and increased sputum production.